Brunner HI, et al. - Authors sought to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous (SC) abatacept in cases with polyarticular-course juvenile idiopathic arthritis (pJIA) over 24 months. Results demonstrated that weight-stratified SC abatacept produced target therapeutic exposures in the age and weight groups. It appeared to be well tolerated and improved the symptoms of pJIA.